ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
ImmuCell (Nasdaq: ICCC) has announced it will release its unaudited financial results for Q4 and full-year 2024 after market close on February 25, 2025. The company will host a conference call on February 26, 2025, at 9:00 AM ET to discuss these results.
The company confirms there are no changes to the preliminary sales results disclosed on January 9, 2025, and expects to file its Annual Report on Form 10-K by March 31, 2025. An updated Corporate Presentation will be available on the company's website after market close on February 25, 2025.
ImmuCell, which focuses on developing products for dairy and beef cattle health, manufactures First Defense® for newborn calf immunity and is developing Re-Tain® for treating subclinical mastitis in dairy cows without FDA-required milk discard or meat withhold restrictions.
ImmuCell (Nasdaq: ICCC) ha annunciato che rilascerà i risultati finanziari non verificati per il quarto trimestre e per l'intero anno 2024 dopo la chiusura del mercato il 25 febbraio 2025. L'azienda ospiterà una conference call il 26 febbraio 2025, alle 9:00 AM ET, per discutere di questi risultati.
L'azienda conferma che non ci sono modifiche ai risultati di vendita preliminari divulgati il 9 gennaio 2025 e prevede di presentare il suo Rapporto Annuale sul Modulo 10-K entro il 31 marzo 2025. Una Presentazione Aziendale aggiornata sarà disponibile sul sito web dell'azienda dopo la chiusura del mercato il 25 febbraio 2025.
ImmuCell, che si concentra sullo sviluppo di prodotti per la salute del bestiame da latte e da carne, produce First Defense® per l'immunità dei vitelli appena nati e sta sviluppando Re-Tain® per il trattamento della mastite subclinica nelle mucche da latte senza restrizioni di scarto del latte o di ritiro della carne richieste dalla FDA.
ImmuCell (Nasdaq: ICCC) ha anunciado que publicará sus resultados financieros no auditados para el cuarto trimestre y el año completo 2024 después del cierre del mercado el 25 de febrero de 2025. La compañía llevará a cabo una conferencia telefónica el 26 de febrero de 2025, a las 9:00 AM ET, para discutir estos resultados.
La compañía confirma que no hay cambios en los resultados de ventas preliminares divulgados el 9 de enero de 2025 y espera presentar su Informe Anual en el Formulario 10-K antes del 31 de marzo de 2025. Una Presentación Corporativa actualizada estará disponible en el sitio web de la compañía después del cierre del mercado el 25 de febrero de 2025.
ImmuCell, que se centra en desarrollar productos para la salud del ganado lechero y de carne, fabrica First Defense® para la inmunidad de los terneros recién nacidos y está desarrollando Re-Tain® para tratar la mastitis subclínica en vacas lecheras sin restricciones de descarte de leche o retención de carne requeridas por la FDA.
ImmuCell (Nasdaq: ICCC)는 2025년 2월 25일 시장 마감 후 2024년 4분기 및 연간 재무 결과를 발표할 것이라고 발표했습니다. 이 회사는 2025년 2월 26일 오전 9시(동부 표준시)에 이러한 결과를 논의하기 위한 컨퍼런스 콜을 개최할 예정입니다.
회사는 2025년 1월 9일에 발표된 초기 판매 결과에 변경 사항이 없음을 확인하며, 2025년 3월 31일까지 10-K 양식의 연례 보고서를 제출할 것으로 예상하고 있습니다. 업데이트된 기업 프레젠테이션은 2025년 2월 25일 시장 마감 후 회사 웹사이트에서 확인할 수 있습니다.
ImmuCell은 유제품 및 육우 건강을 위한 제품 개발에 주력하고 있으며, 신생 송아지의 면역력을 위한 First Defense®를 제조하고 있으며, FDA에서 요구하는 우유 폐기 또는 육류 보류 제한 없이 유제품에서 아급성 유방염을 치료하기 위한 Re-Tain®을 개발하고 있습니다.
ImmuCell (Nasdaq: ICCC) a annoncé qu'elle publiera ses résultats financiers non audités pour le quatrième trimestre et l'année complète 2024 après la clôture du marché le 25 février 2025. L'entreprise tiendra une conférence téléphonique le 26 février 2025 à 9h00 ET pour discuter de ces résultats.
L'entreprise confirme qu'il n'y a aucun changement dans les résultats préliminaires des ventes divulgués le 9 janvier 2025 et s'attend à soumettre son Rapport Annuel sur le Formulaire 10-K d'ici le 31 mars 2025. Une Présentation d'Entreprise mise à jour sera disponible sur le site web de l'entreprise après la clôture du marché le 25 février 2025.
ImmuCell, qui se concentre sur le développement de produits pour la santé des bovins laitiers et de viande, fabrique First Defense® pour l'immunité des veaux nouveau-nés et développe Re-Tain® pour traiter la mastite subclinique chez les vaches laitières sans restrictions de rejet de lait ou de rétention de viande requises par la FDA.
ImmuCell (Nasdaq: ICCC) hat angekündigt, dass es seine ungeprüften Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 nach Marktschluss am 25. Februar 2025 veröffentlichen wird. Das Unternehmen wird am 26. Februar 2025 um 9:00 Uhr ET eine Telefonkonferenz abhalten, um diese Ergebnisse zu besprechen.
Das Unternehmen bestätigt, dass es keine Änderungen an den am 9. Januar 2025 veröffentlichten vorläufigen Verkaufszahlen gibt und erwartet, seinen Jahresbericht auf Formular 10-K bis zum 31. März 2025 einzureichen. Eine aktualisierte Unternehmenspräsentation wird nach Marktschluss am 25. Februar 2025 auf der Unternehmenswebsite verfügbar sein.
ImmuCell, das sich auf die Entwicklung von Produkten für die Gesundheit von Milch- und Fleischrindern konzentriert, stellt First Defense® für die Immunität von neugeborenen Kalb und entwickelt Re-Tain® zur Behandlung von subklinischer Mastitis bei Milchkühen, ohne dass die FDA erforderliche Milchabgabe oder Fleischverweigerung erforderlich ist.
- None.
- None.
Conference Call Scheduled for Wednesday, February 26, 2025 at 9:00 AM ET
PORTLAND, Maine, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter and year ended December 31, 2024 after the market closes on Tuesday, February 25, 2025.
The Company is planning to host a conference call the next morning, Wednesday, February 26, 2025, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until March 5, 2025 at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing replay access code #5555700.
The Company anticipates no change to the preliminary sales results for the fourth quarter and year ended December 31, 2024 that were disclosed on January 9, 2025. The Company expects to file its Annual Report on Form 10-K on or before Monday, March 31, 2025.
Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business which can be accessed under the “Investors” tab of the Company’s website at www.immucell.com, or by request to the Company. An updated version of the slide deck will be made available after the market closes on Tuesday, February 25, 2025.
About ImmuCell:
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef calves. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or meat withhold label restrictions that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.
| Contacts: | Michael F. Brigham, President and CEO ImmuCell Corporation (207) 878-2770 Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC (602) 889-9700 iccc@lythampartners.com |
FAQ
When will ImmuCell (ICCC) release its Q4 and full-year 2024 financial results?
How can investors join ImmuCell's (ICCC) Q4 2024 earnings conference call?
When will ImmuCell (ICCC) file its 2024 Annual Report on Form 10-K?
What are the main products in ImmuCell's (ICCC) portfolio?
